Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.97 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.97 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | GLA | P06280 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320226 | 0.99 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL25090487 | 0.87 | ADORA2B (0.79) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL10723936 | 0.83 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL516013 | 0.81 | ADORA2B (0.77) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL516029 | 0.80 | ADORA2B (0.75) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL7318169 | 0.80 | KDM4E (0.76) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL25090491 | 0.80 | ADORA2B (0.75) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL515588 | 0.80 | KDM4E (0.76) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| 8-Phenyl Theophylline SCHEMBL516432 | 0.80 | ADORA2A (1.00) | ADORA2BADORA2AKDM4EADORA3ADORA1 | |
| SCHEMBL1321892 | 0.80 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245715-A1 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | UNIV OF ALASKA FAIRBANKS (US) | 2024-07-25 | — | — | US | disclosed |
| US-11911408-B2 | Synergistic formulations of adenosine receptor modulating agents and anticholinergics | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220288099-A1 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | UNIVERSITY OF ALASKA FAIRBANKS | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288099-A1 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | ADORA1, ADORA3, ADORA2A | ADORA2B 5/4885ADORA2A 3/4885KDM4E 4464/4885 |
| US-20240245715-A1 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | ADORA1, ADORA3, ADORA2A | ADORA2B 5/4885ADORA2A 3/4885KDM4E 4464/4885 |
| US-11911408-B2 | Synergistic formulations of adenosine receptor modulating agents and anticholinergics | ADORA1, ADORA3, ADORA2A | ADORA2B 5/4885ADORA2A 3/4885KDM4E 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.